Receptor-interacting protein 1 kinase inhibition therapeutically ameliorates experimental T cell-dependent colitis in mice
Cell Death Dis
.
2020 Apr 6;11(4):220.
doi: 10.1038/s41419-020-2423-2.
Authors
Thomas Gobbetti
#
1
,
Scott B Berger
#
2
,
Kathryn Fountain
3
,
Tom Slocombe
3
,
Alison Rowles
4
,
Gail Pearse
4
,
Isobel Harada
5
,
John Bertin
2
,
Andrea C Haynes
#
3
,
Allison M Beal
#
2
Affiliations
1
Adaptive Immunity Research Unit, GlaxoSmithKline, Stevenage, Hertfordshire, UK. thomas.x.gobbetti@gsk.com.
2
Innate Immunity Research Unit, GlaxoSmithKline, Collegeville, PA, USA.
3
Adaptive Immunity Research Unit, GlaxoSmithKline, Stevenage, Hertfordshire, UK.
4
Department of Pathology, GlaxoSmithKline, Ware, Hertfordshire, UK.
5
DMPK, GlaxoSmithKline, Stevenage, Hertfordshire, UK.
#
Contributed equally.
PMID:
32249785
PMCID:
PMC7136199
DOI:
10.1038/s41419-020-2423-2
No abstract available
MeSH terms
Animals
Colitis / drug therapy*
Disease Models, Animal
Female
Humans
Mice
Mice, SCID
T-Lymphocytes / metabolism*